<DOC>
	<DOCNO>NCT01099202</DOCNO>
	<brief_summary>The goal clinical research study learn Procrit ( epoetin alfa ) decrease need blood transfusion patient Acute Lymphocytic Leukemia ( ALL ) , Lymphoblastic Lymphoma ( LL ) , Burkitt 's receive chemotherapy . Another goal study remission rate patient cancer receive treatment epoetin alfa .</brief_summary>
	<brief_title>Procrit Versus No Procrit Acute Lymphocytic Leukemia , Lymphoblastic Lymphoma , Burkitt 's Undergoing Induction/Consolidation Chemotherapy</brief_title>
	<detailed_description>Epoetin alfa medication help body make red blood cell . Before treatment complete physical exam . You around 1 tablespoon blood drawn blood test ( test addition routine blood test part standard care ) . Women able child must negative blood pregnancy test . You randomly assign ( toss coin ) one two treatment group . Patients first group give epoetin alfa week time chemotherapy start . Patients group receive epoetin alfa , undergo laboratory exam quality life evaluation group patient give epoetin alfa . Patients group receive transfusion hemoglobin drop certain level doctor feel necessary . These transfusion consider standard care . You ask keep diary listing date transfusion receive . If assign receive epoetin alfa , give epoetin alfa week regularly schedule chemotherapy . You receive treatment epoetin alfa 6 course chemotherapy ( usually around 5 month , may longer ) . Epoetin alfa give injection skin . Once week , around 1 tablespoon blood drawn check level hemoglobin blood . If hemoglobin rise certain level , treatment epoetin alfa may temporarily stop hemoglobin level decrease . Patients group continue receive chemotherapy study schedule . During chemotherapy , around 1 tablespoon blood drawn every 1-2 week routine blood test ( part standard care treatment cancer ) . If agree optional procedure , continue receive epoetin alfa even hemoglobin level show respond epoetin alfa treatment . However , choose take part optional procedure respond epoetin alfa treatment , take study . If experience intolerable side effect result epoetin alfa disease get bad , take study . This investigational study . Epoetin alfa FDA approve commercially available . Around 164 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>1 . Patients diagnosis ALL , LL , Burkitt 's receive induction chemotherapy HyperCVAD , variant HyperCVAD augment BFM MD Anderson Cancer Center . 2 . Patients must enrol study + / ( plus minus ) 14 day start induction chemotherapy . 3 . Patients relapse ALL , LL , Burkitt 's eligible , must remission duration 1 year longer . 1 . Hemoglobin great equal 10 g/dL . 2 . Patients prior treatment epoetin alfa investigational form erythropoietin within previous 3 month . 3 . Patients know hypersensitivity mammaliancell derive product human albumin . 4 . Uncontrolled hypertension 5 . History thrombotic vascular event . 6 . Pregnant lactating woman . 7 . Anemia due factor cancer , deficiency B12 , folate , iron ( concurrent treatment deficiency ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Procrit</keyword>
	<keyword>Acute Lymphocytic Leukemia</keyword>
	<keyword>Lymphoblastic Lymphoma</keyword>
	<keyword>Burkitt 's</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Hyper-CVAD</keyword>
	<keyword>augment BFM</keyword>
	<keyword>Epoetin alfa</keyword>
	<keyword>Epogen</keyword>
	<keyword>Erythropoietin</keyword>
</DOC>